Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) | RFA DA 25 012

FAQs: Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) - RFA-DA-25-012

What is the title of this funding opportunity?

The opportunity is titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)" and is identified as RFA-DA-25-012.

What type of grant mechanism is this?

This is an NIH R01 research project grant mechanism, intended for substantial, hypothesis-driven projects with a strong conceptual framework and rigorous experimental approach.

Who is the funding agency?

The funding agency is the National Institutes of Health (NIH).

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 93.279.

What is the overall purpose of this funding opportunity?

The purpose is to support mechanistic, non-clinical-trial studies that clarify how inflammasomes contribute to brain and nervous system damage (neuropathology) in the context of HIV infection and substance use, including when the central nervous system is exposed to HIV, drugs of abuse, or both together.

What scientific theme or problem is NIH trying to address with this RFA?

The central theme is inflammasome biology as a driver of immune activation and neuroinflammation in the central nervous system under conditions of HIV exposure, substance exposure, or their combination. NIH is aiming to move the field from broad descriptions of inflammation toward precise identification of specific inflammasome pathways, triggers, downstream mediators, and immune cell populations that cause or sustain damage and immune dysregulation.

Why are inflammasomes a key focus in HIV and substance use research?

The announcement highlights inflammasomes as a potentially shared molecular link between viral infection (HIV) and drug-related immune changes. By mapping these pathways, researchers may be able to explain overlapping mechanisms that drive neuroinflammation and immune activation across both conditions.

What kinds of studies does this opportunity support?

The opportunity supports mechanistic studies that investigate how inflammasomes contribute to CNS immune activation, neuroinflammation, and nervous system damage in HIV and substance use contexts. Projects are expected to be hypothesis-driven and focused on clarifying specific pathways, signals, and downstream inflammatory mediators.

Is this opportunity focused on the central nervous system (CNS)?

Yes. The RFA emphasizes inflammasome-driven immune activation and neuroinflammation when the CNS is exposed to HIV, drugs of abuse, or both, either acutely or over long durations. The focus includes brain and nervous system damage and the immune dysregulation associated with CNS involvement.

Does NIH expect applicants to compare HIV-only, substance-only, and combined effects?

Yes. The description specifically calls out the need to differentiate the effects of HIV alone, drug exposure alone, and the synergistic or additive effects when HIV and substance use occur together.

What is meant by "Clinical Trial Not Allowed" for this R01?

"Clinical Trial Not Allowed" means applicants should not propose studies that assign human participants to an intervention in order to evaluate health-related outcomes. The funded work is expected to be mechanistic and/or preclinical, and may include human-subjects research only if it does not meet NIH's definition of a clinical trial (for example, observational work or studies using existing samples or existing data without assigning an intervention).

Can projects include human subjects at all?

Yes, human-subjects research may be included if it is not an interventional clinical trial. Based on the description provided, allowable human research examples would include observational studies or analyses using existing samples and/or existing datasets, as long as the study does not involve assigning participants to an intervention to test outcomes.

Are preclinical or laboratory-based approaches appropriate under this opportunity?

Yes. The RFA indicates projects are expected to be preclinical and/or mechanistic and may include laboratory-based studies, animal models, and other experimental systems that can clarify inflammasome mechanisms relevant to HIV and substance use.

What kinds of outcomes or deliverables is NIH looking for from funded studies?

The description points to several intended outcomes: (1) identification of specific inflammasome pathways and signals responsible for neuropathology and immune dysregulation; (2) identification of downstream inflammatory mediators that drive or sustain neuroinflammation; (3) discovery or validation of measurable molecular markers (biomarkers) related to risk, neuropathology, or disease progression in substance-using populations affected by HIV; and (4) identification of the CNS immune cell populations most involved in these inflammatory responses.

What is the translational relevance NIH is aiming for if clinical trials are not allowed?

The opportunity emphasizes translational relevance without conducting an interventional clinical trial. The stated long-term payoff is to enable better tools for tracking risk and disease progression (such as biomarkers) and to build evidence for therapeutic strategies that inhibit or modulate inflammasome activation to reduce neuroinflammation and restore healthier immune signaling.

Is the intent to develop therapies under this grant?

The description suggests a longer-term goal of informing therapeutic strategies that modulate inflammasome activation. The immediate purpose of the funded work, however, is mechanistic: to pinpoint which inflammasome-related pathways and mediators are responsible for pathology and immune dysregulation, thereby laying the groundwork for future therapeutic development.

What is the award ceiling?

The posted award ceiling is $500,000.

When is the application closing date?

The original application closing date is March 13, 2025.

How many awards does NIH expect to make?

The listing notes "ExpectedAwards:" without providing a number. The description indicates NIH intends to make multiple awards depending on the availability of funds and the merit of applications, which is typical for NIH RFAs.

Who is eligible to apply?

Eligibility is broad and includes many domestic applicant types, such as state, county, city/township, and special district governments; independent school districts; public and state-controlled colleges and universities; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding higher education institutions for those categories); for-profit organizations other than small businesses; and small businesses.

Are institutions serving specific communities explicitly encouraged or included?

Yes. The opportunity highlights additional eligible applicant groups to encourage broad participation, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, HBCUs, Tribally Controlled Colleges and Universities, eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations).

Are non-U.S. (foreign) organizations eligible?

Yes. The eligibility description explicitly includes non-U.S. entities (foreign organizations).

Are for-profit organizations allowed to apply?

Yes. The eligibility list includes for-profit organizations other than small businesses, and it also separately includes small businesses.

Does this funding opportunity emphasize inclusion and broad participation?

Yes. The wide range of eligible organization types and the explicit naming of institutions and organizations serving diverse communities signal an emphasis on inclusive participation and an expectation that impactful work may come from many settings, including community-connected organizations and institutions serving populations disproportionately affected by HIV and substance use.

What specific biological mechanisms are of interest?

The opportunity focuses on inflammasome pathways, the signals that activate them, and downstream inflammatory mediators that contribute to immune activation, neuroinflammation, neuropathology, and immune dysregulation in the overlapping contexts of HIV and substance use.

What role do biomarkers play in this program?

Biomarker identification is a highlighted goal. NIH is looking to enable researchers to identify measurable molecular markers that can track inflammatory responses, risk, or disease progression, particularly among people with HIV who use substances.

Does the RFA specify particular CNS immune cell populations to study?

The RFA does not name specific cell populations in the provided description, but it explicitly calls for identifying which CNS immune cell populations are most involved in the inflammatory responses associated with HIV infection and disease progression among people who use substances.

Is the focus limited to short-term exposure scenarios?

No. The description includes both acute exposure and long-duration exposure to HIV, drugs of abuse, or the combination, indicating interest in mechanisms operating across time scales.

What public health challenge is this RFA trying to address?

The program targets intertwined public health challenges where HIV infection and substance use overlap and contribute to neuroinflammation, nervous system damage, and immune dysregulation. The intent is to generate precise mechanistic knowledge that can improve tracking and inform future strategies to reduce CNS inflammation and related harms.